Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum

被引:60
作者
Ernst, S
Venkataraman, G
Winkler, S
Godavarti, R
Langer, R
Cooney, CL
Sasisekharan, R
机构
[1] MIT, DEPT CHEM ENGN, CAMBRIDGE, MA 02139 USA
[2] MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA
关键词
D O I
10.1042/bj3150589
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of heparin for extracorporeal therapies has been problematical due to haemorrhagic complications; as a consequence, heparinase I from Flavobacterium heparimum is used for the determination of plasma heparin and for elimination of heparin from circulation. Here we report the expression of recombinant heparinase I in Escherichia coli, purification to homogeneity and characterization of the purified enzyme. Heparinase I was expressed with an N-terminal histidine tag. The enzyme was insoluble and inactive, but could be refolded, and was purified to homogeneity by nickel-chelate chromatography. The cumulative yield was 43 %, and the recovery of purified heparinase I was 14.4 mg/l of culture, The N-terminal sequence and the molecular mass as analysed by matrix-assisted laser desorption MS were consistent with predictions from the heparinase I gene structure. The reverse-phase HPLC profile of the tryptic digest, the Michaelis-Menten constant K-m (47 mu g/ml) and the specific activity (117 units/mg) of purified recombinant heparinase I were similar to those of the native enzyme. Degradation of heparin by heparinase I results in a characteristic product distribution, which is different from those obtained by degradation with heparinase II or III from F. heparimum. We developed a rapid anion-exchange HPLC method to separate the products of enzymic heparin degradation, using POROS perfusion chromatography media. Separation of characteristic di-, tetra- and hexasaccharide products is performed in 10 min. These methods for the expression, purification and analysis of recombinant heparinase I may facilitate further development of heparinase I-based medical therapies as well as further investigation of the structures of heparin and heparan sulphate and their role in the extracellular matrix.
引用
收藏
页码:589 / 597
页数:9
相关论文
共 64 条
[1]  
Abildgaard U., 1989, HEPARIN CHEM BIOL PR, P495
[2]   HEPARINASE IN THE ACTIVATED CLOTTING TIME ASSAY - MONITORING HEPARIN-INDEPENDENT ALTERATIONS IN COAGULATION FUNCTION [J].
BAUGH, RF ;
DEEMAR, KA ;
ZIMMERMANN, JJ .
ANESTHESIA AND ANALGESIA, 1992, 74 (02) :201-205
[3]  
BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
Comper W.D, 1981, HEPARIN RELATED POLY
[6]   SUBSTRATE-SPECIFICITY OF THE HEPARIN LYASES FROM FLAVOBACTERIUM-HEPARINUM [J].
DESAI, UR ;
WANG, HM ;
LINHARDT, RJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 306 (02) :461-468
[7]  
DIETRICH CP, 1973, J BIOL CHEM, V248, P6108
[8]   ANALYSIS OF GLYCOPROTEIN-ASSOCIATED OLIGOSACCHARIDES [J].
DWEK, RA ;
EDGE, CJ ;
HARVEY, DJ ;
WORMALD, MR ;
PAREKH, RB .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :65-100
[9]   ENZYMATIC DEGRADATION OF GLYCOSAMINOGLYCANS [J].
ERNST, S ;
LANGER, R ;
COONEY, CL ;
SASISEKHARAN, R .
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 30 (05) :387-444
[10]   BIOREACTOR BASED ON SUSPENDED PARTICLES OF IMMOBILIZED ENZYME [J].
FREED, LE ;
VUNJAKNOVAKOVIC, GV ;
DRINKER, PA ;
LANGER, R .
ANNALS OF BIOMEDICAL ENGINEERING, 1993, 21 (01) :57-65